Progress in scale up of HIV viral load testing in select sub-Saharan African countries 2016-2018.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
05
2022
accepted:
19
02
2023
entrez:
15
3
2023
pubmed:
16
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
We assessed progress in HIV viral load (VL) scale up across seven sub-Saharan African (SSA) countries and discussed challenges and strategies for improving VL coverage among patients on anti-retroviral therapy (ART). A retrospective review of VL testing was conducted in Côte d'Ivoire, Kenya, Lesotho, Malawi, Namibia, Tanzania, and Uganda from January 2016 through June 2018. Data were collected and included the cumulative number of ART patients, number of patients with ≥ 1 VL test result (within the preceding 12 months), the percent of VL test results indicating viral suppression, and the mean turnaround time for VL testing. Between 2016 and 2018, the proportion of PLHIV on ART in all 7 countries increased (range 5.7%-50.2%). During the same time period, the cumulative number of patients with one or more VL test increased from 22,996 to 917,980. Overall, viral suppression rates exceeded 85% for all countries except for Côte d'Ivoire at 78% by June 2018. Reported turnaround times for VL testing results improved in 5 out of 7 countries by between 5.4 days and 27.5 days. These data demonstrate that remarkable progress has been made in the scale-up of HIV VL testing in the seven SSA countries.
Identifiants
pubmed: 36920918
doi: 10.1371/journal.pone.0282652
pii: PONE-D-22-15612
pmc: PMC10016655
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0282652Subventions
Organisme : PEPFAR
Pays : United States
Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
AIDS Res Hum Retroviruses. 2005 Dec;21(12):1031-4
pubmed: 16379606
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):775-778
pubmed: 34043612
Lancet Infect Dis. 2018 Nov;18(11):e362-e367
pubmed: 29980383
J Acquir Immune Defic Syndr. 2020 Jul 1;84 Suppl 1:S56-S62
pubmed: 32520916
Lancet HIV. 2018 Nov;5(11):e667-e670
pubmed: 30314745
J Clin Microbiol. 2019 Mar 28;57(4):
pubmed: 30728197
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1287-90
pubmed: 26605986
Afr J Lab Med. 2014;3(3):
pubmed: 26752335
PLoS One. 2018 Sep 19;13(9):e0201341
pubmed: 30231022
AIDS Res Hum Retroviruses. 2020 Jul;36(7):550-555
pubmed: 32070109
J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29130605
AIDS Rev. 2009 Apr-Jun;11(2):59-70
pubmed: 19529746
J Infect Dis. 2016 Apr 15;213 Suppl 2:S59-64
pubmed: 27025700
MMWR Morb Mortal Wkly Rep. 2016 Dec 02;65(47):1332-1335
pubmed: 27906910
Clin Infect Dis. 2016 Apr 15;62(8):1043-8
pubmed: 26743094
PLoS One. 2018 Mar 2;13(3):e0193577
pubmed: 29499042
PLoS One. 2013 Nov 13;8(11):e78609
pubmed: 24236026
PLoS One. 2017 Feb 24;12(2):e0173009
pubmed: 28235013
Clin Infect Dis. 2017 Mar 15;64(6):796-803
pubmed: 28200031
AIDS Res Hum Retroviruses. 2018 Feb;34(2):132-139
pubmed: 28967269
Diagnostics (Basel). 2020 Dec 24;11(1):
pubmed: 33374315
J Acquir Immune Defic Syndr. 2017 Apr 01;74(4):399-406
pubmed: 28002185